Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
Are Medical Stocks Lagging Alkermes (ALKS) This Year?
10:41am, Tuesday, 21'st Oct 2025
Here is how Alkermes (ALKS) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Is Alkermes (ALKS) Stock Undervalued Right Now?
10:41am, Tuesday, 21'st Oct 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Alkermes to Report Third Quarter Financial Results on October 28, 2025
04:00pm, Monday, 20'th Oct 2025
DUBLIN , Oct. 20, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m.
Alkermes Appoints Joshua Reed as Chief Financial Officer
09:00am, Friday, 12'th Sep 2025
DUBLIN , Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept.
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
07:00am, Thursday, 11'th Sep 2025
— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar I Disorder
Alkermes Plc (ALKS) World Sleep Congress 2025 (Transcript)
02:34pm, Monday, 08'th Sep 2025
Alkermes plc (NASDAQ:ALKS ) World Sleep Congress 2025 Conference September 8, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Rich
– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of Doses – �
Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report?
12:31pm, Thursday, 28'th Aug 2025
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severit
Alkermes: A More Than Solid Quarter
05:08pm, Wednesday, 30'th Jul 2025
Alkermes plc is a mid-cap and quite profitable commercial-stage biopharma company, and we are revisiting it today for the first time in a year. The company just reported Q2 financial results, with pro
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales
11:26am, Wednesday, 30'th Jul 2025
ALKS beats second-quarter estimates as proprietary product sales rise 14% y/y, offsetting weaker manufacturing and royalty revenues.
Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript
02:47pm, Tuesday, 29'th Jul 2025
Alkermes plc (NASDAQ:ALKS ) Q2 2025 Earnings Call July 29, 2025 8:00 AM ET Company Participants Blair C. Jackson - Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO C.
Alkermes (ALKS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
10:31am, Tuesday, 29'th Jul 2025
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimate
Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates
09:25am, Tuesday, 29'th Jul 2025
Alkermes (ALKS) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.72 per share a year ago.
Alkermes plc Reports Second Quarter 2025 Financial Results
07:00am, Tuesday, 29'th Jul 2025
— Second Quarter Revenues of $390.7 Million — — GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 — — Company Reiterates 2025 Financial Expectat
